StockWatch
·
ICICI LOMBARD · Q2 FY27 · PREVIEW

Motor reserve bites, health surges — can Q2 reset the trajectory?

After Q1's 46% profit crash from SC-mandated motor reserves and fire losses, ICICI Lombard's Q2 print hinges on whether claims normalise and health momentum sticks. Street remains cautious but sees long-term runway.

Q2 FY27 resultsICICIGIICICI Lombard General Insurance Company Ltd08 Oct 2026 · 3 min read

The setup: Motor reserve exhausted, now the recovery

Q1 FY27 delivered a painful 46% profit crash—from ₹747 Cr in Q1 FY26 to ₹403 Cr—driven by two major fire incidents and a pre-emptive ₹165 Cr reserve against ICICI Lombard's Motor Third-Party (TP) portfolio, following the Supreme Court's July 2026 ruling that raised compensation benchmarks. The motor TP loss ratio across the industry is now expected to jump 12–15 percentage points. Q2 will test whether that reserve was sufficient and whether the motor segment's underlying profitability stabilises. The real story: health and fire grew double-digits in H1; if that momentum carries into Q2, combined-ratio normalisation is achievable.

Expected net earned premium (NEP)

~₹5,900–6,000 Cr

On-plan 12–15% YoY growth; Q2 FY26 was ₹5,380 Cr, Q1 FY27 ₹5,950 Cr

Expected combined ratio

~102–105%

Q1 FY27 at 107.2% (elevated); normalisation post-reserve, but motor TP still headwind

Expected PAT

~₹600–₹650 Cr

vs Q1 ₹403 Cr (post-reserve hit); Q2 FY26 ₹820 Cr base, but motor drag persists

Health premium trajectory

~₹750–800 Cr NEP

Q1 growth +24.9% YoY, retail health up 47.3% H1 FY27; market share gains intact

A strong Q2 would show combined ratio back below 105%, PAT north of ₹650 Cr, and sustained double-digit growth in health and fire premiums—evidence that the motor TP reserve was adequate and pricing discipline is working. A weak Q2 would signal further claims acceleration in motor, a combined ratio above 106%, PAT below ₹600 Cr, and slowing health growth—forcing another round of guidance cuts and brokerage downgrades.

On track for FY27 guidance?

ICICI Lombard guided for a 102–103% combined ratio and ~13% CAGR in NEP and PAT over FY26–FY28 at its recent Digital Day (September 29, 2026). Q1's 107.2% combined ratio fell short, but management attributed it to the one-off motor reserve and fire claims—not a structural deterioration. Q2 is the acid test: if combined ratio moves closer to the 102–103% band, the guidance holds water. If motor claims prove stickier (say, combined ratio stays above 105%), a full-year guide revision is likely. Street consensus as of early October is cautious—brokerages expect earnings downsides near-term but see 13% CAGR achievable by FY28 if underwriting discipline sticks.

Recent filings and regulatory headwinds

Key events since Q1 result (July 15, 2026)
  • 1 · Digital Day strategy (Sept 29, 2026)

    ICICI Lombard hosted an Analyst Digital Day, reiterating 102–103% combined-ratio target and 13% CAGR guidance. Messaging focused on market-share gains in health (+47.3% H1) and fire (+27.3% Q2 FY26), and pricing discipline in motor to absorb TP claims hike. This sets a high bar for Q2—any miss on health growth or combined ratio will be read as guidance weakness.

  • 2 · GST and tax demands (Sept–Oct 2026)

    Series of GST demand appeals upheld: ₹2.41 Cr demand + ₹2.64 Cr penalty confirmed by Appeals Authority (Hyderabad); ₹3.34 Lakh demand partially allowed (Chennai). Additionally, ₹1 Crore IRDAI penalty imposed for outsourcing compliance violations (Sept 8). Routine regulatory friction, but collectively a drag on provisions. Watch for one-off charges in Q2 P&L.

  • 3 · Income tax refund erroneous adjustment (Aug 8, 2026)

    IT Department adjusted a refund of ₹96.96 Cr (AY 2025-26) against a demand. Not immediately material to Q2, but flags a tax risk item for FY27. Likely to be disclosed in notes to accounts.

  • 4 · Arbitration loss—₹776.73 Mn award (July 14, 2026)

    ICICI Lombard lost an arbitration case on an insurance dispute involving six insurances on a road project. Award of ₹776.73 Mn due to the insured. Immaterial to Q2 in isolation, but adds to adverse claims trend.

  • 5 · Trading window closure (Sept 28, 2026)

    Insider trading window closed ahead of Q2 FY27 result announcement, per regulation. Routine; no signal.

Key metrics to watch on result day (Oct 14, 2026)

  • 1 · Combined ratio: trajectory to normalisation

    Is combined ratio moving back toward 102–103% guidance, or stuck above 105%? Motor TP loss ratio improvement vs deterioration will drive this—the ₹165 Cr reserve is now sunk, so movement quarter-on-quarter tells you if pricing and risk selection are holding.

  • 2 · Health & fire NEP: sustaining momentum

    Did health premium growth decelerate below 15% YoY? Fire growth above 20%? These are the offset stories to motor drag. If either falters, Street will cut FY27 growth estimates.

  • 3 · Motor NEP and loss ratio

    What is the motor segment's YoY growth? Is loss ratio stabilising above the pre-SC level but not accelerating further? This is the make-or-break metric for the 13% CAGR guidance.

  • 4 · One-off charges and tax provisions

    GST, IRDAI penalty, arbitration loss, and IT refund adjustment may all hit Q2 P&L. Disentangle one-offs from operational profit to judge run-rate earnings.

  • 5 · Dividend & FY27 guidance commentary

    Management commentary on FY27 guidance adherence and any dividend signal will frame Street sentiment post-result. A maintained 13% CAGR target is a positive; a cut is a risk.

ICICI Lombard enters Q2 in a delicate spot: the motor TP reserve is done, but the loss-ratio headwind persists. Health and fire growth have been robust, but if they slow, the offset story breaks. The Street consensus is cautious but not capitulating—brokerages see 13% FY26–FY28 CAGR as achievable if underwriting discipline and market-share gains stick. Q2's combined ratio, health growth, and management guidance remark will determine whether brokerages hold their Buy calls or join the downgrades. The price (₹1,590, +11.7% off its 52-week low) reflects modest optimism; a beat on combined-ratio normalisation and health growth could reignite momentum, while a miss could re-test the lows.

Informational and educational content only. Not investment advice.